Date: 2017-01-25
Type of information: Results
phase: preclinical
Announcement: results
Company: Neovacs (France)
Product: IFN alpha Kinoid
Action
mechanism: kinoid/immunotherapy product. A Kinoid is obtained by chemically linking the cytokine of interest to a foreign carrier protein, KLH ( Keyhole Limpet Hemocyanin), and then treating the resultant compound to inactivate the cytokine. These active immunotherapies have been designed to induce an antibody response (self-polyclonal antibodies) by the patient’s immune system that targets a particular over-expressed cytokine responsible for the pathogenesis and development of a given disease. The Kinoid technology can be applied in principle to any cytokine target.
Disease: type 1 diabetes
Therapeutic area: Autoimmune diseases - Metabolic diseases
Country:
Trial details:
Latest
news: * On January 25, 2017, Neovacs announced the recommendation of its Scientific Advisory Board to extend the development of IFN Kinoid to a new indication, type 1 diabetes, with the objectives of obtaining preclinical proof of concept in 2017 and initiating clinical development for this program in the first half of 2018. The recommendation issued by the Company’s scientific advisory Board is based on achieving a high level of immunogenicity after IFN Kinoid administration, in a relevant preclinical model of Type 1 diabetes. Indeed, Neovacs observed in treated NOD-Mice, a significant level of anti-interferon Alpha neutralizing antibodies. This study was conducted by Neovacs in collaboration with Doctor Agnès Lehuen and Professor Christian Boitard from the department of Immunology of Diabetes at the Hospital Cochin in Paris. The rationale for pursuing Type 1 diabetes is further supported by well-established data showing that overexpression of IFN? plays a key role in this autoimmune disease, as also observed in lupus and dermatomyositis.
The data obtained with IFN Kinoid in preclinical and clinical studies in Lupus conducted by Neovacs, will also be used for clinical development in type 1 diabetes. No additional toxicity study will be needed before initiating a clinical trial, thus accelerating the development timeline for this indication.
